Mumbai: Anthem Biosciences Limited announced on Tuesday its consolidated financial results for the first quarter of the financial year 2026-27. The company's consolidated net profit for the quarter ended 30 June 2026 was ₹119.94 crore.
Revenue Performance
Revenue from operations for the quarter ended 30 June 2026 reached ₹418.22 crore. This marked a decline of 31.54% compared to the ₹610.94 crore reported in the preceding quarter (31 March 2026) and a 22.58% decrease from ₹540.21 crore in the year-ago quarter (30 June 2025).
Profit Before Tax
Profit before tax for the June 2026 quarter was ₹144.58 crore. This is lower than the ₹277.92 crore recorded in the quarter ended 31 March 2026 and the ₹186.25 crore in the quarter ended 30 June 2025.
Total Expenses
Total expenses for the quarter stood at ₹298.53 crore. This represents a decrease from ₹385.22 crore in the preceding quarter and ₹376.77 crore in the year-ago quarter.
Segmental Revenue
The CRDMO segment contributed ₹340.80 crore to the total revenue. The Speciality Ingredients segment generated ₹77.42 crore in revenue for the quarter ended 30 June 2026.
Employee Benefit Expenses
Employee benefit expenses for the quarter were ₹78.84 crore. This is an increase from ₹72.48 crore in the preceding quarter and ₹72.03 crore in the year-ago quarter.
Equity Share Capital
Paid-up equity share capital as of 30 June 2026 was ₹112.68 crore. The company allotted 1,670,909 fully paid-up equity shares under its ESOPScheme 2024 during the quarter.
Disclaimer: This report is based on the company's filed financial results (standalone or consolidated, as applicable) and is intended solely for informational purposes. It does not constitute investment advice or a recommendation to buy, sell or hold any security.
